Indium In-111 pentetreotide

DB11835ApprovedSmall moleculeRadioactive Diagnostic Agent

Indium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.

Mechanism: Pharmacologically active on Somatostatin receptor type 2 and Somatostatin receptor
Curator reviewed
Formula / weight: C₆₂H₈₀InN₁₂O₁₉S₂ · 1472.41 g/mol (avg)
First approval: United States, 2007
Also known as: 111In-Pentetreotide · 111Indium pentetreotide · Indium In 111 Pentreotide
Code names: MP-1727
Brand names: Octreoscan

Resolves to

Compound

CAS139096-04-1PubChem131704321

Clinical / RWD

RxNorm1724429ATCV09IB01

Structure

InChIKeyZKZPXKKVDJOAIS-JWFOFJTQSA-JSMILES

[111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1

Targets

P30874SSTR2

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

4Marketed productsAcross 2 countries and 3 labellers

1ATC codeIncluding every combination product, plus 17 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Indium In-111 pentetreotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account